Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas2Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
JAMA Surg. 2013 Nov;148(11):1024-9. doi: 10.1001/jamasurg.2013.3776.
Recently, preoperative lung cancer staging has evolved to include endobronchial ultrasonography-guided transbronchial needle aspiration (EBUS-TBNA) biopsies of the hilar and mediastinal lymph nodes, but the feasibility and usefulness of the procedure have not been well studied in the veteran population.
To determine the safety and effectiveness of EBUS-TBNA as a key component of a preoperative staging algorithm for lung cancer in veterans.
DESIGN, SETTING, AND PARTICIPANTS: Review of a prospectively maintained thoracic surgery database that includes patients who underwent lung resection for lung cancer between January 1, 2009, and December 31, 2012, at a single Veterans Affairs medical center among a consecutive cohort of 166 patients with clinically early-stage (I or II) lung cancer who underwent lobectomy with nodal dissection.
Endobronchial ultrasonography-guided transbronchial needle aspiration mediastinal staging (EBUS group) in 62 patients (37.3%) was compared with noninvasive nodal staging plus integrated positron emission tomography-computed tomography only (PET/CT-only group) in 104 patients (62.7%). The accuracy of nodal staging was assessed by comparison with the final pathological staging after complete nodal dissection (the gold standard).
Primary outcomes were feasibility, safety, accuracy, and negative predictive value of EBUS-TBNA for preoperative nodal staging. A secondary outcome was the rate of nontherapeutic lung resection for occult N2 disease, with comparison between the EBUS group and the PET/CT-only group.
No significant complications were attributable to the EBUS-TBNA procedure. In the EBUS group, 258 lymph node stations were sampled. N1 hilar metastases were diagnosed in 8 patients (12.9%) before surgery, and the remainder were staged N0. Accuracy and negative predictive value of EBUS-TBNA were 93.5% (58 of 62) and 92.6% (50 of 54), respectively. The overall rate of nontherapeutic lung resection performed in patients with occult N2 disease was 10.8% (18 of 166) (8.1% in the EBUS group and 12.5% in the PET/CT-only group) (P = .37).
A preoperative lung cancer staging strategy that includes EBUS-TBNA seems to be safe and effective in a veteran population, resulting in a low rate of nontherapeutic operations because of occult N2 nodal disease.
最近,肺癌术前分期已发展为包括支气管内超声引导经支气管针吸活检(EBUS-TBNA)对肺门和纵隔淋巴结进行活检,但该程序在退伍军人中的可行性和实用性尚未得到充分研究。
确定 EBUS-TBNA 作为退伍军人肺癌术前分期算法的关键组成部分的安全性和有效性。
设计、地点和参与者:对前瞻性维护的胸外科数据库进行回顾,该数据库包括 2009 年 1 月 1 日至 2012 年 12 月 31 日期间在单一退伍军人事务医疗中心接受肺切除术治疗肺癌的患者,该数据库包括 166 例连续队列中的患者,这些患者患有临床早期(I 期或 II 期)肺癌,接受肺叶切除术和淋巴结清扫术。
在 62 例患者(37.3%)中进行支气管内超声引导经支气管针吸纵隔分期(EBUS 组),并与 104 例仅行非侵入性淋巴结分期加综合正电子发射断层扫描-计算机断层扫描(PET/CT-仅组)进行比较。通过与完全淋巴结清扫后的最终病理分期(金标准)比较,评估淋巴结分期的准确性。
主要结果是 EBUS-TBNA 术前淋巴结分期的可行性、安全性、准确性和阴性预测值。次要结果是隐匿性 N2 疾病的非治疗性肺切除术率,并比较 EBUS 组和 PET/CT-仅组之间的差异。
EBUS-TBNA 操作无明显并发症。在 EBUS 组中,258 个淋巴结站被取样。术前诊断 8 例(12.9%)患者存在 N1 肺门转移,其余患者分期为 N0。EBUS-TBNA 的准确性和阴性预测值分别为 93.5%(58/62)和 92.6%(50/54)。隐匿性 N2 疾病患者行非治疗性肺切除术的总体率为 10.8%(166 例中的 18 例)(EBUS 组为 8.1%,PET/CT-仅组为 12.5%)(P=0.37)。
在退伍军人人群中,包括 EBUS-TBNA 的术前肺癌分期策略似乎是安全有效的,由于隐匿性 N2 淋巴结疾病,非治疗性手术的比例较低。